Recent advances in the treatment of nasopharyngeal carcinoma

Journal of the Formosan Medical Association

Volumn 103, Issue 7, 2004, Pages 496-510

  Chang, Joseph Tung Chieh ^a   Ko, Jenq Yuh ^b   Hong, Ruey Long ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adjuvant chemotherapy; Adoptive; Immunotherapy; Nasopharyngeal neoplasms; Radiotherapy; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LATENT MEMBRANE PROTEIN 2; MITOMYCIN C; NAVELBINE; PACLITAXEL; UFT; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS PROTEIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LONG TERM CARE; MAXILLA RESECTION; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PROGNOSIS; RADIATION DOSE DISTRIBUTION; RADIOSURGERY; REVIEW; SALVAGE THERAPY; SERODIAGNOSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

CARCINOMA; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 6344237620     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Shanmugaratnam K, Sobin LH: The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993;71:2689-97.
2. Neel HB, III, Pearson GR, Taylor WF: Antibody-dependent cellular cytotoxicity. Relation to stage and disease course in North American patients with nasopharyngeal carcinoma. Arch Otolaryngol 1984;110:742-7.
3. Fleming ID, Cooper JS, Harrison DE. American Joint Committee on Cancer: Manual for Staging Cancer. 5th ed. Philadelphia: JB Lippincott, 1997.
4. Ho JHC. Nasopharynx. In: Halnan KE, Boak, JL, Crowther D, et al, editors. Treatment of cancer. 1st ed. London: Chapman and Hall; 1982:249-67.
5. Sham JS, Cheung YK, Choy D, et al: Nasopharyngeal carcinoma: CT evaluation of patterns of tumor spread. AJNR Am J Neuroradiol 1991;12:265-70.
6. Olmi P, Cellai E, Chiavacci A, et al: Computed tomography in nasopharyngeal carcinoma: Part I: T-stage conversion with CT-staging. Int J Radiat Oncol Biol Phys 1990;19:1171-5.
7. Ng SH, Chang JT, Ko SF, et al: MRI in recurrent nasopharyngeal carcinoma. Neuroradiology 1999;41:855-62.
8. Chong VF, Mukherji SK, Ng SH, et al: Nasopharyngeal carcinoma: review of how imaging affects staging. J ComputAssist Tomogr 1999;23:984-93.
9. Kao CH, Shiau YC, Shen YY, et al: Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 2002;94:1981-6.
10. Chen CJ, You SL, Pan WH: Seroepidemiology of Epstein-Barr virus and cytomegalovirus infection among preschool and school children in Taiwan. Clin J Microbiol Immunol 1991;24:150-8.
11. Chen JY, Chen CJ, Liu MY, et al: Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol 1989;27: 269-73.
12. Lynn TC, Tu SM, Kawamura A, Jr.: Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol 1985;99: 567-72.
13. Chen MR, Liu MY, Hsu SM, et al: Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients. J Med Virol 2001; 64:51-7.
14. Hsu MM, Hsu WC, Sheen TS, et al: Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. Clin Otolaryngol 2001;26:334-8.
15. Chien YC, Chen JY, Liu MY, et al: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877-82.
16. Sheen TS, Ko JY, Chang YL, et al: Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck 1998;20:732-8.
17. Lin SY, Tsang NM, Kao SC, et al: Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001; 23:194-200.
18. Jeng KC, Hsu CY, Liu MT, et al: Prevalence of Taiwan variant of Epstein-Barr virus in throat washings from patients with head and neck tumors in Taiwan. J Clin Microbiol 1994;32:28-31.
19. Hao SP, Tsang NM, Chang KP: Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer 2003;97:1909-13.
20. Hsu MM, Tu SM: Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983;52:362-8.
21. Lee AW, Foo W, Law SC, et al: Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int J Cancer 1999;84: 179-87.
22. Chua DT, Sham JS, Kwong DL, et al: Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma. A significant factor in local control and distant metastasis. Cancer 1996;78:202-10.
23. Baker SR: Nasopharyngeal carcinoma: clinical course and results of therapy. Head Neck Surg 1980;3:8-14.
24. Mesic JB, Fletcher GH, Goepfert H: Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 1981;7:447-53.
25. Neel HB: Nasopharyngeal carcinoma. Clinical presentation, diagnosis, treatment, and prognosis. Otolaryngol Clin North Am 1985;18:479-90.
26. Ahmad A, Stefani S: Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol 1986;33: 194-7.
27. Ko JY, Lee TC, Hsiao CF, et al: Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Cancer 2002;94:1987-96.
28. Hwang CF, Su CY, Huang SC, et al: Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett 2003;189:231-6.
29. Hsu CH, Chen CL, Hong RL, et al: Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology 2002;62:305-12.
30. Ho KY, Kuo WR, Chai CY, et al: A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma. Laryngoscope 2001;111: 131-6.
31. Cheng AJ, Chiu DT, See LC, et al: Poor prognosis in nasopharyngeal cancer patients with low glucose-6-phosphate-dehydrogenase activity. Jpn J Cancer Res 2001;92:576-81.
32. Cheng SH, Yen KL, Jian JJ, et al: Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiat Oncol Biol Phys 2001;50:717-26.
33. Jian JJ, Cheng SH, Prosnitz LR, et al: T classification and clivus margin as risk factors for determining locoregional control by radiotherapy of nasopharyngeal carcinoma. Cancer 1998;82: 261-7.
34. Hsiung CY, Wu JM, Wang CJ, et al: Attenuation of radiation dose by the skull base bone in patients with nasopharyngeal carcinoma: clinical importance. Radiology 2001;218:457-63.
35. Cheng SH, Tsai SY, Yen KL, et al: Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 2000;18:2040-5.
36. Lee AW, Law SC, Foo W, et al: Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol 1993;66: 528-36.
37. Levendag PC, Schmitz PI, Jansen PP, et al: Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx. J Clin Oncol 1998;16:2213-20.
38. Chang JT, See LC, Tang SG, et al: The role of brachytherapy in early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996;36:1019-24.
39. Ho JU, Chen YC, Ro CJ, et al: Intracavity brachytherapy for nasopharyngeal carcinoma with Rotterdam nasopharyngeal applicator. Therapeut Radiol Oncol 2001;8:33-41.
40. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
41. Ang KK, Peters LJ, Weber RS, et al: Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990; 19:1339-45.
42. Teo PM, Leung SF, Chan AT, et al: Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 2000;48: 1311-22.
43. Jen YM, Lin YS, Su WF, et al: Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending? Int J Radiat Oncol Biol Phys 2002;54: 14-22.
44. Lee AW, Sze WM, Fowler JF, et al: Caution on the use of altered fractionation for nasopharyngeal carcinoma. Radiother Oncol 1999;52:207-11.
45. Jen YM, Hsu WL, Chen CY, et al: Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques. Int J Radiat Oncol Biol Phys 2001;51:344-8.
46. Jian JJ, Cheng SH, Tsai SY, et al: Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002;53:344-52.
47. Cmelak AJ, Cox RS, Adler JR, et al: Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997;37:997-1003.
48. Chua DT, Sham JS, Kwong PW, et al: Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 2003;56:177-83.
49. Hsu MM, Hong RL, Ting LL, et al: Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site: experience with 60 cases. Arch Otolaryngol Head Neck Surg 2001;127:798-802.
50. Hao SP, Tsang NM, Chang CN: Salvage surgery for recurrent nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:63-7.
51. Chang JT, See LC, Liao CT, et al: Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000;54:135-42.
52. Leibel SA, Kutcher GJ, Harrison LB, et al: Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 1991;20: 823-33.
53. Wolden SL, Zelefsky MJ, Hunt MA, et al: Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2001;49:1229-34.
54. Cheng JC, Chao KS, Low D: Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 2001;96:126-31.
55. Hsiung CY, Yorke ED, Chui CS, et al: Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2002;53:638-47.
56. Lee N, Xia P, Quivey JM, et al: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53: 12-22.
57. Zhang EP, Lian PG, Cai KL, et al: Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys 1989;16:301-5.
58. Teo PM, Kwan WH, Chan AT, et al: How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998;40:897-913.
59. Bedwinek JM, Perez CA, Keys DJ: Analysis of failures after definitive irradiation for epidermoid carcinoma of the nasopharynx. Cancer 1980;45:2725-9.
60. Shu CH, Shiau CY, Chi KH, et al: Salvage surgery for recurrent nasopharyngeal carcinoma in anterior marginal miss after radiotherapy. Otolaryngol Head Neck Surg 1999;121:622.
61. Cocke EW, Jr., Robertson JH, Robertson JT, et al: The extended maxillotomy and subtotal maxillectomy for excision of skull base tumors. Arch Otolaryngol Head Neck Surg 1990;116:92-104.
62. Tu GY, Hu YH, Xu GZ, et al: Salvage surgery for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1988;114:328-9.
63. Fee WE Jr, Roberson JB Jr, Goffinet DR: Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. Arch Otolaryngol Head Neck Surg 1991; 117:1233-6.
64. Wei WI, Ho CM, Yuen PW, et al: Maxillary swing approach for resection of tumors in and around the nasopharynx. Arch Otolaryngol Head Neck Surg 1995;121:638-42.
65. Morton RP, Liavaag PG, McLean M, et al: Transcervico-mandibulo-palatal approach for surgical salvage of recurrent nasopharyngeal cancer. Head Neck 1996;18:352-8.
66. King WW, Ku PK, Mok CO, et al: Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck 2000;22:215-22.
67. Hsu MM, Hong RL, Ting LL, et al: Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site: experience with 60 cases. Arch Otolaryngol Head Neck Surg 2001;127:798-802.
68. Hsu HC, Chen CL, Hsu MM, et al: Pathology of nasopharyngeal carcinoma. Proposal of a new histologic classification correlated with prognosis. Cancer 1987;59:945-51.
69. Hsu MM, Ko JY, Sheen TS, et al: Salvage surgery for recurrent nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:305.
70. Wei WI, Lam KH, Sham JS: New approach to the nasopharynx: the maxillary swing approach. Head Neck 1991;13:200-7.
71. Shu CH, Cheng H, Lirng JF, et al: Salvage surgery for recurrent nasopharyngeal carcinoma. Laryngoscope 2000;110:1483-8.
72. Hao SP, Tsang NM, Chang CN: Salvage surgery for recurrent nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:63-7.
73. Yan JH, Hu YH, Gu XZ: Radiation therapy of recurrent nasopharyngeal carcinoma. Report on 219 patients. Acta Radiol Oncol 1983;22:23-8.
74. Yen KL, Hsu LP, Sheen TS, et al: Salvage neck dissection for cervical recurrence of nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:725-9.
75. Chi KH, Chang YC, Chan WK, et al: A phase II study of carboplatin in nasopharyngeal carcinoma. Oncology 1997; 54:203.
76. Au E, Ang PT: A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994;5:87-9.
77. Wang TL, Tan YO: Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 1991;20:601-3.
78. Chi KH, Chan WK, Cooper DL, et al: A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer 1994;73:247.
79. Ho WK, Wei WI, Kwong DL, et al: Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 1999;21:547-53.
80. Young YH, Lu YC: Mechanism of hearing loss in irradiated ears: a long-term longitudinal study. Ann Otol Rhinol Laryngol 2001; 110:904-6.
81. Lou PJ, Chen WP, Tai CC: Delayed irradiation effects on nasal epithelium in patients with nasopharyngeal carcinoma. An ultrastructural study. Ann Otol Rhinol Laryngol 1999;108: 474-80.
82. Booth D, Potten CS: Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 2001; 16-20.
83. Chi KH, Chan WK, Shu CH, et al: Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 1995;76:2186.
84. Hong RL, Sheen TS, Ko JY, et al: Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br J Cancer 1999; 80:1962.
85. Clark JR, Dreyfuss AI: The role of cisplatin in treatment regimens for squamous cell carcinoma of the head and neck. Semin Oncol 1991;18:34-48.
86. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
87. Rockwell S: Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo. J Natl Cancer Inst 1983;71:765-71.
88. Fandi A, Bachouchi M, Azli N, et al: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000;18:1324-30.
89. Foo KF, Tan EH, Leong SS, et al: Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002;13:150-6.
90. Au E, Tan EH, Ang PT: Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol 1998;9:327-9.
91. Tan EH, Khoo KS, Wee J, et al: Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999;10:235-7.
92. Yeo W, Leung TW, Chan AT, et al: A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998;34:2027-31.
93. McCarthy JS, Tannock IF, Degendorfer P, et al: A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 2002;38:686-90.
94. Ngan RK, Yiu HH, Lau WH, et al: Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002;13:1252-8.
95. Chua DT, Sham JS, Au GK: A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003;39:361-6.
96. Airoldi M, Pedani F, Marchionatti S, et al: Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 2002;88:273-6.
97. Fossella FV, Lynch T, Shepherd FA: Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002;38:5-12.
98. Odaka K, Fujimura M, Yoshida T, et al: Autologous bone marrow transplantation in the treatment of nasopharyngeal carcinoma - report of 2 cases [in Japanese]. Gan To Kagaku Ryoho 1983;10: 245-53.
99. Geara FB, Sanguineti G, Tucker SL, et al: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997;43:53-61.
100. Heng DM, Wee J, Fong KW, et al: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999;86:1912-20.
101. Fandi A, Altun M, Azli N, et al: Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994;21: 382-97.
102. Rossi A, Molinari R, Boracchi P, et al: Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6: 1401-10.
103. Chi KH, Chang YC, Guo WY, et al: A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44.
104. Thomas GM: Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340:1198-200.
105. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
106. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
107. Al Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-7.
108. Cheng SH, Jian JJ, Tsai SY, et al: Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000;48:1323.
109. Serin M, Erkal HS, Cakmak A: Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol 1999;38:1031-5.
110. Chan AT, Teo PM, Ngan RK, et al: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20: 2038-44.
111. Lin JC, Jan JS, Hsu CY, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631.
112. Tan EH, Chua ET, Wee J, et al: Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999;45:597-601.
113. Cooper JS: Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx. Int J Radiat Oncol Biol Phys 2000;48:1277-9.
114. Ahmad A, Stefani S: Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol 1986;33: 194-7.
115. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996;35:463-9.
116. Chua DT, Sham JS, Choy D, et al: Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998;83:2270-83.
117. Ma J, Mai HQ, Hong MH, et al: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19: 1350-7.
118. Milas L, Nakayama T, Hunter N, et al: Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 1994;30:247-53.
119. Withers HR, Taylor JM, Madejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
120. Laramore GE, Scott CB, Al Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992;23:705-13.
121. Hong RL, Ting LL, Ko JY, et al: Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19: 4305-13.
122. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
123. Chan AT, Hsu MM, Goh BC, et al: A Phase II study of cetuximab (C225) in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma who failed to a platinum-based chemotherapy. Proceeding of Am Soc Clin Oncol 2003;2000.
124. Miller WE, Earp HS, Raab-Traub N: The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995;69:4390.
125. Lu J, Chua HH, Chen SY, et al: Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 2003; 63:256.
126. Sheen TS, Huang YT, Chang YL, et al: Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 1999;90:1285.
127. Guan E, Zhou TC, Wang JH, et al: Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Int J Cell Cloning 1989;7:242.
128. Sun Y, Fry DW, Vincent P, et al: Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res 1999;19:919.
129. Lin CL, Lo WF, Lee TH, et al: Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002;62:6952-8.
130. Al Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.